President-elect Donald Trump's promise to dismantle the Affordable Care Act is unlikely to also undo widespread efforts to nudge the U.S. healthcare system toward value-based payment, including experiments devised by the ACA-funded CMS Innovation Center.
Read Full Release
It's that time of year in Boston when you have 75 degree weekends followed immediately by 35 degree Mondays. We get it, Beantown is not an ideal destination at the moment. HOWEVER, this week our team will be opening up our office to advisors, investors, and other industry minds to hold a week of BrainTrust™ brainstorming sessions that cover Product Strategy, Workflow and Operations, Future Technology, and Marketing and Productizing. Video conference attendees are welcome.
Read Full Release
MedAptus® today announced the availability of real-time analytics, the Hospitalist Risk Series, that leverage patient history and admission activity to identify those at greatest risk for re-admissions, and also helps providers better manage resources related to length of stay. The new Series, aimed primarily at hospitalists on the front line of acute patient care, is available through the MedAptus Professional Charge Capture (Pro) suite. This latest offering extends the Pro solution’s ability to compute data from admission/discharge feeds and diagnosis history in order to meaningfully impact key metrics around hospitalizations that hospital medicine providers are increasingly responsible for.
Read Full Release
While bold, the goal of the Cancer Moonshot is within our grasp. Today, society has the benefit of
decades of scientific understanding and vast amounts of rich data just waiting to be transformed into
solutions. We now know that cancer is hundreds of diseases, largely of our genome, and we have
developed new and innovative ways of capitalizing on this knowledge. We know that our behavior and
environment contribute to our likelihood of getting cancer, and we are modifying our behaviors and
exposures to avoid known risks. We know that prevention and early diagnosis are key to fighting cancer,
and we can build these efforts into clinical care.
Read Full Release
The U.S. Department of Transportation (DOT) is proposing a new rule that would set maximum travel speeds for heavy-duty vehicles. Set forth by the DOT’s National Highway Traffic Safety Administration (NHTSA) and Federal Motor Carrier Safety Administration (FMCSA), the new rule is expected to save lives and more than $1 billion in fuel annually.
Read Full Release
The 2016 New England Regional Innovation Summit is a two-day engagement opportunity being held at MIT, for technology innovators and entrepreneurs. This effort, spearheaded by the SBA Office of Investment and Innovation (OII), is a coordinated effort amongst participating SBIR/STTR agencies to continually engage, identify, and encourage participation in the SBIR/STTR programs. The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs, affectionately referred as America’s Seed Fund, play an instrumental role in providing early stage, non-dilutive, research and development capital which spurs small advanced technology firms’ innovations. Annually more than $2.5 billion non-diluted in early stage research and development funding is provided through these programs.
Read Full Release
Following recent share performance that has shares almost doubling in the past two
weeks, we continue to see room for share appreciation as the Xtampza ER launch has
clear tailwinds as we exit the summer through 2017. Management has signed at least
one large managed care win with UnitedHealth (UNH $140.00) and we believe
additional managed care wins are likely during the fourth quarter as well as the
potential for comparative data between OxyContin and Xtampza ER being added to
label. Admittedly, the Xtampza ER launch was slow as management chose to launch
during the summer months despite the historically slow season, which was
compounded by a lack of approved marketing materials. However, the company
recently received approved marketing materials and given formulary wins (both
UnitedHealth and likely additional wins), we should see a ramping up of scripts over
the next quarter and into 2017.
Read Full Release
Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the publication of “Oral Human Abuse Potential of Oxycodone DETERx® (Xtampza® ER),” in the peer-reviewed medical journal, The Journal of Clinical Pharmacology.
The publication presents the results from a human abuse potential (HAP) study, which was designed to evaluate the abuse potential and pharmacokinetics of oral administration of intact Xtampza® ER (oxycodone extended-release), oral administration of chewed Xtampza ER, and oral administration of crushed immediate-release oxycodone in non-dependent, recreational drug abusers.
Read Full Release
Today’s financing environment for emerging biotech companies presents a number of challenges. Venture capital funds are ever more cautious about taking risk, and some players have departed the field at the early stage. Government grants have also closed their spigots in recent years, as the volume of government funding has plummeted dramatically. However, new players have entered the fray in the last few years, including family offices, super angels, strategic partners and foreign investors, replacing the investment dollars previously offered by institutional investors. So where does an emerging biotech company forage for precious dollars? Come join us on September 22nd at the CIC in Cambridge to hear a panel of experts discuss these trends. At the event, you will discover, among other ideas:
Where and how to find the new players;
What areas of interest are these players financing;
How to optimize your chances of success;
What are deal structures looking like?
Read Full Release
From early startups to growth-stage companies to highly successful businesses, the CED Tech Venture Conference reflects North Carolina’s vibrant entrepreneurial community and showcases many of the most-promising emerging companies in the region. Attendees will have the opportunity to connect with a diverse group of over 100 investors, from venture capital to corporate to angels, including funds such as Sequoia Capital, Greycroft, Grotech Ventures, and Comcast Ventures. Engage with industry leaders, radical thinkers and trail-blazing entrepreneurs, and learn about the disruptive innovations that are transforming the ways in which we live, work and play.
Read Full Release
